chufangao/CTO huggingface dataset:
Clinical trial NCT02514447: Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Official title: Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Sponsor: G1 Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns.
Enrollment: 123.0 (ACTUAL)
Number of arms: 9.0
Start date: 2015-10-05
Primary completion date: 2018-09-28
Completion date: 2021-10-04
Limitations and caveats: Limitation of the trial is small numbers of subjects, since it is a Phase 2 clinical trial.~Small sample size may have reduced the ability to observe statistically significant treatment effects on secondary myelopreservation measures (i.e. occurrence of FN AEs, infections and antibiotics usage).
Plan to share individual participant data: NO
Clinical trial NCT02097810: Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
Official title: A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations
Acronym: STARTRK-1
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 84.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-07-28
Primary completion date: 2020-06-02
Completion date: 2020-06-02
Clinical trial NCT03448692: A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
Official title: A PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Acronym: PODO
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to lack of efficacy at both tested doses on 5th December 2022. The decision to terminate the study is not related to a safety concern.
Enrollment: 47.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-15
Primary completion date: 2023-02-14
Completion date: 2023-02-14
Baseline population: Safety Analysis Set (SAS) was defined as all enrolled participants who had received at least one dose of study treatment.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04973228: Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Official title: A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis
Sponsor: Arcutis Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 457.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-08
Primary completion date: 2022-04-06
Completion date: 2022-04-06
Plan to share individual participant data: NO
Clinical trial NCT04776850: Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
Official title: Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe Hemoglobinopathies
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Competing protocol opened in Adult SCT that will include pediatric patients and is now multi-center. No patients enrolled on study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-29
Primary completion date: 2022-12-05
Completion date: 2022-12-05
Clinical trial NCT04323280: Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis
Official title: Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis: a Non-inferiority Randomized Controlled Trial (Dexa-P)
Acronym: Dexa-P
Sponsor: Rabin Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulty in enrollment of patients
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-14
Primary completion date: 2023-07-17
Completion date: 2023-07-17
Plan to share individual participant data: NO
Clinical trial NCT03592407: Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
Official title: A Phase 2 Trial of Neoadjuvant Pembrolizumab in Combination With Epacadostat (INCB024360) in Patients With Non-Metastatic Esophageal/Gastroesophageal Squamous Cell and Adenocarcinomas Treated With Neoadjuvant Chemoradiation: A Window-Of-Opportunity Study
Sponsor: City of Hope Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Safety concerns
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-01
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT03578029: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
Official title: A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
Acronym: CELEB
Sponsor: Lenus Therapeutics, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-22
Primary completion date: 2021-09-01
Completion date: 2021-11-23
Plan to share individual participant data: NO
Clinical trial NCT03345095: A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
Official title: A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Acronym: MIRAGE
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 749.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-26
Primary completion date: 2022-08-23
Completion date: 2023-06-30
Clinical trial NCT02562612: Study of SM-88 in Advanced Cancers
Official title: Ascending Multi-Dose Clinical Trial to Assess the Pharmacokinetics Efficacy of SM-88 Oral Administration in Breast Cancer Subjects
Sponsor: Tyme, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Study was never initiated. Never established sites or enrolled subjects.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-31
Primary completion date: 2023-10-31
Completion date: 2023-10-31
Clinical trial NCT03784222: Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
Official title: Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Company's business decision
Enrollment: 102.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-22
Primary completion date: 2022-11-22
Completion date: 2022-11-22
Plan to share individual participant data: NO
Clinical trial NCT03254927: A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Official title: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Sponsor: Celldex Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision based on emerging risk-benefit profile
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-27
Primary completion date: 2020-09-16
Completion date: 2020-12-16
Limitations and caveats: Study was terminated early due to unfavorable risk/benefit profile.
Clinical trial NCT02156154: Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications
Official title: Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 580.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-31
Primary completion date: 2019-03-31
Completion date: 2020-10-31
Clinical trial NCT02298166: Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
Official title: Dose-Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
Sponsor: University of Ulm (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an Investigator Initiated Trial this became valid on 2020/03/09
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-17
Primary completion date: 2020-03-09
Completion date: 2020-03-09
Clinical trial NCT03705507: International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
Official title: International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Acronym: SeluDex
Sponsor: University of Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Poor recruitment, due to a change in the standard of care for this patient population with the use of CAR-T cells
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-18
Primary completion date: 2023-05-03
Completion date: 2023-05-03
Plan to share individual participant data: YES
IPD sharing description: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. The CRCTU is committed to responsible and controlled sharing of anonymised clinical trial data with the wider research community to maximise potential patient benefit while protecting the privacy and confidentiality of trial participants. Data anonymised in compliance with the Information Commissioners Office requirements, using a procedure based on guidelines from the MRC Methodology Hubs, will be available for sharing with researchers outside of the trials team within 6 months of the primary publication. More detailed information on the CRCTU's Data Sharing Policy and the mechanism for obtaining data can be found on the CRCTU website: https://www.birmingham.ac.uk/research/activity/mds/trials/crctu/index.aspx.
IPD time frame: Data will be available within 6 months of the primary publication.
IPD access criteria: See Plan Description above.
Clinical trial NCT05139615: A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of APD418 in Subjects With Heart Failure With Reduced Ejection Fraction
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 22.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-28
Primary completion date: 2022-09-19
Completion date: 2022-09-19
Baseline population: Full analysis set included all randomized participants, irrespective of whether they received any study treatment.
Limitations and caveats: This study was terminated early due to a business decision that was not due to any safety concerns. The number of participants was smaller than originally planned and only summary statistics were therefore generated for primary and secondary outcome measures.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03707028: A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Official title: A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Sponsor: Elevar Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated after completion of Part 1 due to a change in research plan.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-01
Primary completion date: 2021-08-24
Completion date: 2021-08-24
Clinical trial NCT03483883: Avelumab/Gemcitabine in Sarcomatoid RCC
Official title: A Phase I/IB Study of Avelumab in Combination With Gemcitabine for Advanced Renal Cell Carcinoma With Sarcomatoid Differentiation
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated due to protracted accrual and limited patient engagement in the setting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features and/or intermediate/poor risk clinical features.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-19
Primary completion date: 2020-07-22
Completion date: 2021-02-10
Clinical trial NCT05079230: Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Acronym: ENHANCE-3
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was terminated due to futility
Enrollment: 378.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-07
Primary completion date: 2024-04-11
Completion date: 2024-04-11
Plan to share individual participant data: NO
Clinical trial NCT03462966: Rifaximin on Visceral Hypersensitivity
Official title: Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: recruitment challenges
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-01
Primary completion date: 2021-11-19
Completion date: 2021-11-19
Limitations and caveats: recruitment challenges and the COVID pandemic affected our enrollment as we were only able to enroll 4 participants and not all of them finished the outcome measures.
Clinical trial NCT02369549: Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
Official title: Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
Acronym: MPAC-CKD
Sponsor: Lawson Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 518.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-30
Primary completion date: 2019-11-30
Completion date: 2020-05-15
Plan to share individual participant data: NO
Clinical trial NCT05762744: Pharmacogenomics of GLP1 Receptor Agonists
Official title: Pharmacogenomics of GLP1 Receptor Agonists
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: We concluded that it would not be possible to meet our recruitment targets within the available budget. The study was ended when the funding ended.
Enrollment: 78.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-06-01
Primary completion date: 2018-11-30
Completion date: 2022-10-31
Plan to share individual participant data: YES
IPD sharing description: Subject to protection of confidential information of research participants, we will share data with qualified researchers.
IPD time frame: 12 months after publication in a peer reviewed journal.
IPD access criteria: Must sign data transfer agreement to protect confidentiality of research participants.~Requester must be on faculty at an accredited academic institution such as a medical school.
Clinical trial NCT03013491: PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Official title: An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas
Sponsor: CytomX Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 300.0 (ESTIMATED)
Number of arms: 5.0
Start date: 2017-01-31
Primary completion date: 2021-10-06
Completion date: 2021-10-06
Clinical trial NCT03089606: Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Official title: Pembrolizumab in Systemic Treatment-Naïve Distant Metastatic Melanoma and Exploration of Use of Baseline 11C-methyl-L-tryptophan (C11-AMT) PET Imaging as a Predictive Imaging Biomarker of Antitumor Response
Sponsor: UNC Lineberger Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-19
Primary completion date: 2021-04-01
Completion date: 2023-07-01
Plan to share individual participant data: NO
Clinical trial NCT03376854: Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS
Official title: Pilot Randomized Clinical Trial of Therapeutic Hypothermia Plus Neuromuscular Blockade vs. Standard of Care in COVID-19 Patients With Moderate to Severe ARDS - the Cooling to Help Injured Lungs (CHILL) Pilot Study
Acronym: CHILL-pilot
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Competition from other studies and initiation of a larger multi center trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-01
Primary completion date: 2021-04-27
Completion date: 2021-04-27
Plan to share individual participant data: YES
IPD sharing description: At the completion of the study, Dr. Hasday and colleagues will present the results of the long-term outcomes at national meetings and publish them in peer-reviewed journals and in ClinicalTrials.gov. Within one year of the publication of the main trial data (whichever occurs first, Dr. Hasday will make de-identified study data available to any individual who presents an appropriate question and analysis plan. The available information will include 1) descriptive documents (e.g. study protocol, code book/variable dictionary, data collection instruments, and de-identification methodology), and 2) de-identified data file.
IPD time frame: All information will be available within one year of the publication of the main trial data.
IPD access criteria: Access will either be by email to Dr. Hasday or through a website to be developed.
Clinical trial NCT05673109: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AC176 in Chinese Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sponsor: Accutar Biotechnology Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-22
Primary completion date: 2023-10-08
Completion date: 2023-10-08
Plan to share individual participant data: NO
Clinical trial NCT03204305: Brain Imaging of Cannabinoid Receptors
Official title: Brain Imaging of Cannabinoid Receptors in Women
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-14
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Baseline population: There were 21 female cannabis users and 7 female healthy control nonusers enrolled. Of these, 10 of the female cannabis users and 2 healthy control female nonusers completed the full protocol and were included in the analysis. Due to low recruitment for healthy controls, 8 historical female healthy controls were included in analysis. We also conducted an analysis that compared all female controls (n=10; 2 healthy controls and 8 matched historical controls) with male historical controls.
Plan to share individual participant data: NO
Clinical trial NCT04160468: Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis
Acronym: DISRUPT
Sponsor: ContraFect (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.
Enrollment: 259.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-20
Primary completion date: 2022-09-09
Completion date: 2022-09-09
Baseline population: Microbiological intent-to-treat (mITT) analysis set
Clinical trial NCT03022565: Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
Official title: Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Investigator Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-31
Primary completion date: 2020-01-29
Completion date: 2020-01-29
Plan to share individual participant data: NO